Community-acquired pneumonia: An unfinished battle

Medical Clinics of North America

Volumn 95, Issue 6, 2011, Pages 1143-1161

  Nair, Girish B ^a   Niederman, Michael S ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Community acquired pneumonia; Lungs; Mortality; Pneumococcus

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC THERAPY; CLINICAL EVALUATION; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; HUMAN; INFLUENZA; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; PATHOGENESIS; PHYSICAL EXAMINATION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; SEPSIS; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT FAILURE; UNITED STATES;

ALGORITHMS; BIOLOGICAL MARKERS; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; HUMANS; INTENSIVE CARE; LEGIONNAIRES' DISEASE; LUNG; LUNG DISEASES; MEDICAL HISTORY TAKING; PHYSICAL EXAMINATION; PNEUMONIA; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPUTUM;

EID: 82455172268     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2011.08.007     Document Type: Review

References (67)

1. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S2-S27.
2. Brar N.K., Niederman M.S. Management of community-acquired pneumonia: a review and update. Ther Adv Respir Dis 2011, 5:61-78.
3. Kochanek KD, Xu J, Murphy SL, et al. Deaths: Preliminary data for 2009. National Vital Statistics Reports 59, No. 4.CDC 2011. Available at: Accessed 30, June 2011. http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_04.pdf.
4. Heron MP, Hoyert DL, Murphy SL, et al. Deaths: Final data for 2006. National Vital Statistics Reports 57. National Center for Health Statistics2009. Available at: Accessed 10, July 2011. http://www.cdc.gov/nchs/fastats/pneumonia.htm.
5. Fine M.J., Smith M.A., Carson C.A., et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996, 275:134-141.
6. Welte T., Köhnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ network. Semin Respir Crit Care Med 2009, 30:127-135.
7. Kaplan V., Clermont G., Griffin M.F., et al. Pneumonia: still the old man's friend?. Arch Intern Med 2003, 163:317-323.
8. File T.M., Marrie T.J. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010, 122:130-141.
9. Kozma C.M., Dickson M., Raut M.K., et al. Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP). J Med Econ 2010, 13:719-727.
10. Capelastegui A., Espana P.P., Quintana J.M., et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006, 27:151.
11. Aujesky D., Auble T.E., Yealy D.M., et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005, 118:384-392.
12. Niederman M.S. Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin. Clin Infect Dis 2008, 47:S127-S132.
13. Wunderink R.G., Waterer G.W. Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infect Dis Clin North Am 2004, 18:743-759.
14. Sarkar M., Hennessy S., Yang Y.X. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008, 149:391-398.
15. Waterer G.W., Bruns A.H. Genetic risk of acute pulmonary infections and sepsis. Expert Rev Respir Med 2010, 4:229-238.
16. Niederman M.S., Ahmed Q.A. Inflammation in severe pneumonia: act locally, not globally. Crit Care Med 1999, 27:2030-2032.
17. Lieberman D. Atypical pathogens in community-acquired pneumonia. Clin Chest Med 1999, 20:489-497.
18. Paganin F., Lilienthal F., Bourdin A., et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J 2004, 24:779-785.
19. Kang C.I., Song J.H., Oh W.S., et al. Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group. Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli. Eur J Clin Microbiol Infect Dis 2008, 27:657-661.
20. Boyer A., Amadeo B., Vargas F., et al. Severe community-acquired Enterobacter pneumonia: a plea for greater awareness of the concept of health-care-associated pneumonia. BMC Infect Dis 2011, 11:120.
21. Arancibia F., Bauer T.T., Ewig S., et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002, 162:1849-1858.
22. de Roux A., Marcos M.A., Garcia E., et al. Viral community-acquired pneumonia in non immunocompromised adults. Chest 2004, 125:1343-1351.
23. Niederman M.S. In the clinic - community-acquired pneumonia. Ann Intern Med 2009, 151. ITC1-14.
24. Lobo L.J., Reed K.D., Wunderink R.G. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest 2010, 138:130-136.
25. Francis J.S., Doherty M.C., Lopatin U., et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005, 40:100-107.
26. Diep B.A., Chambers H.F., Graber C.J., et al. Emergence of multidrug-resistant, community associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008, 148:249-257.
27. Torres A., Menendez R., Wunderink R. Infectious disease of lung. Murray and Nadel's Textbook of Respiratory Medicine. [Chapter: Pyogenic Bacterial Pneumonia and Lung Abscess] vol. 1 2010, 699-740. Saunders, Philadelphia. 5th edition. R.J. Mason, S.O. Their (Eds.).
28. Metlay J.P., Kapoor W.N., Fine M.J. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997, 278:1440-1445.
29. Mandell L.A., Marrie T.J., Grossman R.F., et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000, 31:383-421.
30. van der Eerden M.M., Vlaspolder F., de Graaff C.S., et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005, 60:672-678.
31. van der Eerden M.M., Vlaspolder F., de Graaff C.S., et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005, 24:241-249.
32. Mirsaeidi M., Peyrani P., Aliberti S., et al. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest 2010, 137:416-420.
33. Nair V., Niederman M.S., Masani N., et al. Hyponatremia in community-acquired pneumonia. Am J Nephrol 2007, 27:184-190.
34. Hopstaken R.M., Witbraad T., van Engelshoven J.M., et al. Inter-observer variation in the interpretation of chest radiographs for pneumonia in community-acquired lower respiratory tract infections. Clin Radiol 2004, 59:743-752.
35. Syrjälä H., Broas M., Suramo I., et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998, 27:358-363.
36. Metersky M.L., Ma A., Bratzler D.W., et al. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004, 169:342-347.
37. Smith M.D., Derrington P., Evans R., et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 2003, 41:2810-2813.
38. Ortega L., Sierra M., Domínguez J., et al. Utility of a pneumonia severity index in the optimization of the diagnostic and therapeutic effort for community-acquired pneumonia. Scand J Infect Dis 2005, 37:657-663.
39. Benin A.L., Benson R.F., Besser R.E. Trends in legionnaire's disease, 1980-1998: declining mortality and new patterns of diagnosis. Clin Infect Dis 2002, 35:1039-1046.
40. Sordé R., Falcó V., Lowak M., et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med 2011, 171:166-172.
41. Krüger S., Ewig S., Giersdorf S., et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010, 182:1426-1434.
42. Ramírez P., Ferrer M., Martí V., et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011, [Epub ahead of print]. PMID:21705887.
43. Almirall J., Bolíbar I., Toran P., et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004, 125:1335-1342.
44. Schuetz P., Suter-Widmer I., Chaudri A., et al. Procalcitonin-Guided Antibiotic Therapy and Hospitalisation in Patients with Lower Respiratory Tract Infections (ProHOSP) Study Group. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 2011, 37:384-392.
45. Müller F., Christ-Crain M., Bregenzer T., et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010, 138:121-129.
46. Christ-Crain M., Stolz D., Bingisser R., et al. Procalcitonin guidance of antibiotic therapy in community- acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174:84-93.
47. Renaud B., Santin A., Coma E., et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community acquired pneumonia. Crit Care Med 2009, 37:2867-2874.
48. Restrepo M.I., Mortensen E.M., Rello J., et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010, 137:552-557.
49. Aujesky D., McCausland J.B., Whittle J., et al. Reasons why emergency department providers do not rely on the Pneumonia Severity Index to determine the initial site of treatment for patients with pneumonia. Clin Infect Dis 2009, 49:100-108.
50. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
51. Valencia M., Badia J.R., Cavalcanti M., et al. Pneumonia severity index class V patients with community-acquired pneumonia: characteristics, outcomes, and value of severity. Chest 2007, 132:515-522.
52. Brito V., Niederman M.S. Predicting mortality in the elderly with community-acquired pneumonia: should we design a new car or set a new 'speed limit'?. Thorax 2010, 65:944-945.
53. Bauer T.T., Ewig S., Marre R., et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006, 260:93-101.
54. Blot S.I., Rodriguez A., Solé-Violán J., et al. Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med 2007, 35:2509-2514.
55. Huang D.T., Weissfeld L.A., Kellum J.A., et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008, 52:48-58.
56. Kruger S., Ewig S., Marre R., et al. Procalcitonin predicts patients at low risk of death from community acquired pneumonia across all CRB-65 classes. Eur Respir J 2008, 31:349-355.
57. Liapikou A., Ferrer M., Polverino E., et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis 2009, 48:377-385.
58. Brown S.M., Jones B.E., Jephson A.R., et al. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med 2009, 37:3010-3016.
59. Rello J., Rodriguez A., Lisboa T., et al. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med 2009, 37:456-462.
60. Charles P.G., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008, 47:375-384.
61. Houck P.M., Bratzler D.W., Nsa W., et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004, 164:637-644.
62. Meehan T.P., Fine M.J., Krumholz H.M., et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997, 278:2080-2084.
63. Metersky M.L., Ma A., Houck P.M., et al. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007, 131:466-473.
64. Baddour L.M., Yu V.L., Klugman K.P., et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170:440-444.
65. Leroy O., Saux P., Bédos J.P., et al. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005, 128:172-183.
66. Rodríguez A., Mendia A., Sirvent J.M., et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007, 35:1493-1498.
67. Ramirez J.A., Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001, 161:848-850.